MRS. LYMARIS GARCIA-MEDINA MD
Prescription History 1740508191
Internal Medicine - Pulmonary Disease in Hudson, NY

NPI Status: Active since May 10, 2010

Contact Information

71 PROSPECT AVE
HUDSON, NY
ZIP 12534
Phone: (518) 697-7823

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for MRS. LYMARIS GARCIA-MEDINA MD, an active Pulmonary Disease specialist practicing in Hudson, NY. Our medical registry currently tracks 31 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 2,634 documented patient claims. Among these therapy options, the most frequently utilized medication is Albuterol Sulfate Hfa, which accounts for 581 claims alone.


Advair Diskus

Generic Formulation: Fluticasone Propion/SalmeterolSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 33
30-Day Fills 70.0
Days Supply 2,100
NY State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills36.8
Peer Average Days Supply1,100
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 26.9% more claims than the standard regional baseline profile for NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $30,343.40 across this reporting matrix range.

Provider Avg Cost Per Claim

$919.50

State Avg Cost Per Claim

$588.17

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). It contains 2 medications: fluticasone and salmeterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Salmeterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as salmeterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with one asthma-control medication (such as inhaled corticosteroid) or if your symptoms need combination treatment. Before using this medication, it is important to learn how to use it properly. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Albuterol Sulfate Hfa

Generic Formulation: Albuterol SulfateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 581
30-Day Fills 793.7
Days Supply 20,762
NY State Average Benchmarks
Peer Average Claims66.0
Peer Average 30-Day Fills79.4
Peer Average Days Supply2,056
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 780.3% higher than the standard regional baseline profile for NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $27,963.45 across this reporting matrix range.

Provider Avg Cost Per Claim

$48.13

State Avg Cost Per Claim

$47.16

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.

Therapeutic Applications

Albuterol (also known as salbutamol) is used to treat wheezing and shortness of breath caused by breathing problems such as asthma. It is a quick-relief medication. Albuterol belongs to a class of drugs known as bronchodilators. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school.

Anoro Ellipta

Generic Formulation: Umeclidinium Brm/Vilanterol TrSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 157
30-Day Fills 223.0
Days Supply 6,690
NY State Average Benchmarks
Peer Average Claims35.0
Peer Average 30-Day Fills46.1
Peer Average Days Supply1,372
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 348.6% higher than the standard regional baseline profile for NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $103,689.30 across this reporting matrix range.

Provider Avg Cost Per Claim

$660.44

State Avg Cost Per Claim

$600.87

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Controlling symptoms of breathing problems helps you stay active. This inhaler contains 2 medications: umeclidinium and vilanterol. Both drugs work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Umeclidinium belongs to a class of drugs known as anticholinergics. Vilanterol belongs to the class of drugs known as long-acting beta agonists (LABAs). Both drugs are also known as bronchodilators. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If sudden breathing problems occur, use your quick-relief inhaler as prescribed. Umeclidinium/vilanterol is not approved to treat asthma. People with asthma using long-acting inhaled beta agonists (such as vilanterol) without also using an inhaled corticosteroid may have an increased risk of serious (sometimes fatal) breathing problems.

Arnuity Ellipta

Generic Formulation: Fluticasone FuroateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 20
30-Day Fills 34.0
Days Supply 1,020
NY State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills35.9
Peer Average Days Supply1,073
Conservative Utilization

This provider writes prescriptions for this formulation 25.9% less frequently than the standard regional baseline metric for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $8,638.28 across this reporting matrix range.

Provider Avg Cost Per Claim

$431.91

State Avg Cost Per Claim

$300.92

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Fluticasone is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma. Controlling symptoms of asthma helps you maintain your normal activities and decreases time lost from work or school. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing swelling (inflammation) of the airways in the lungs to make breathing easier. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Atrovent Hfa

Generic Formulation: Ipratropium BromideSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 14
30-Day Fills 14.0
Days Supply 417
NY State Average Benchmarks
Peer Average Claims17.0
Peer Average 30-Day Fills20.1
Peer Average Days Supply566
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $7,007.22 across this reporting matrix range.

Provider Avg Cost Per Claim

$500.52

State Avg Cost Per Claim

$545.82

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A muscarinic antagonist structurally related to ATROPINE but often considered safer and more effective for inhalation use. It is used for various bronchial disorders, in rhinitis, and as an antiarrhythmic.

Therapeutic Applications

Ipratropium is used to control and prevent symptoms (wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD which includes bronchitis and emphysema). It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. For preventing symptoms of lung disease, this medication must be used regularly to be effective. Use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) for wheezing or sudden shortness of breath unless otherwise directed by your doctor. Ipratropium does not work as fast as your quick-relief inhaler, but may sometimes be used to relieve symptoms of wheezing or sudden shortness of breath if so prescribed by your doctor.

Azithromycin

Generic Formulation: AzithromycinSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 91
30-Day Fills 107.2
Days Supply 1,525
NY State Average Benchmarks
Peer Average Claims38.0
Peer Average 30-Day Fills39.4
Peer Average Days Supply295
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 139.5% higher than the standard regional baseline profile for NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,380.24 across this reporting matrix range.

Provider Avg Cost Per Claim

$15.17

State Avg Cost Per Claim

$8.47

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A semi-synthetic macrolide antibiotic structurally related to ERYTHROMYCIN. It has been used in the treatment of Mycobacterium avium intracellulare infections, toxoplasmosis, and cryptosporidiosis.

Therapeutic Applications

This medication is used to treat certain eye infections. It is a macrolide antibiotic that works by stopping the growth of bacteria. This medication treats only bacterial eye infections. It will not work for other types of eye infections. Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Bevespi Aerosphere

Generic Formulation: Glycopyrrolate/Formoterol FumSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 27
30-Day Fills 47.0
Days Supply 1,410
NY State Average Benchmarks
Peer Average Claims19.0
Peer Average 30-Day Fills26.0
Peer Average Days Supply777
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 42.1% more claims than the standard regional baseline profile for NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $20,647.86 across this reporting matrix range.

Provider Avg Cost Per Claim

$764.74

State Avg Cost Per Claim

$570.49

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Controlling symptoms of breathing problems helps you maintain your normal activities and decreases time lost from work or school. This inhaler contains 2 medications: glycopyrrolate and formoterol. Both drugs work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Glycopyrrolate belongs to a class of drugs known as anticholinergics. Formoterol belongs to the class of drugs known as long-acting beta agonists (LABAs). Both drugs are also known as bronchodilators. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden breathing problems. If sudden shortness of breath occurs, use your quick-relief inhaler as prescribed. Glycopyrrolate/formoterol is not approved to treat asthma. People with asthma using long-acting inhaled beta agonists (such as formoterol) without also using an inhaled corticosteroid may have an increased risk of serious (sometimes fatal) breathing problems.

Breo Ellipta

Generic Formulation: Fluticasone/VilanterolSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 85
30-Day Fills 136.0
Days Supply 4,080
NY State Average Benchmarks
Peer Average Claims37.0
Peer Average 30-Day Fills50.0
Peer Average Days Supply1,491
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 129.7% higher than the standard regional baseline profile for NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $55,991.25 across this reporting matrix range.

Provider Avg Cost Per Claim

$658.72

State Avg Cost Per Claim

$531.93

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to prevent and decrease symptoms (wheezing and trouble breathing) caused by asthma and ongoing lung disease (chronic obstructive pulmonary disease-COPD, including chronic bronchitis and emphysema). This inhaler contains 2 medications: fluticasone and vilanterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing the swelling of the airways in the lungs to make breathing easier. Vilanterol belongs to a class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. When used alone, long-acting beta agonists (like vilanterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with one asthma-control medication (such as inhaled corticosteroid) or if your symptoms need combination treatment. Before using this medication, it is important to learn how to use it properly. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Breztri Aerosphere

Generic Formulation: Budesonide/Glycopyr/FormoterolSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 100
30-Day Fills 147.0
Days Supply 4,410
NY State Average Benchmarks
Peer Average Claims41.0
Peer Average 30-Day Fills52.7
Peer Average Days Supply1,578
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 143.9% higher than the standard regional baseline profile for NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $95,048.78 across this reporting matrix range.

Provider Avg Cost Per Claim

$950.49

State Avg Cost Per Claim

$799.94

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Controlling symptoms of breathing problems helps you maintain your normal activities and decreases time lost from work or school. This inhaler contains 3 medications: budesonide, glycopyrrolate, and formoterol. Budesonide works by reducing the irritation and swelling of the airways. Budesonide belongs to a class of drugs known as corticosteroids. Glycopyrrolate and formoterol work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Glycopyrrolate belongs to a class of drugs known as anticholinergics. Formoterol belongs to the class of drugs known as long-acting beta agonists (LABAs). Both drugs are also known as bronchodilators. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden breathing problems. If sudden shortness of breath occurs, use your quick-relief inhaler as prescribed. This medication is not approved to treat asthma.

Budesonide-Formoterol Fumarate

Generic Formulation: Budesonide/Formoterol FumarateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 36
30-Day Fills 70.0
Days Supply 2,100
NY State Average Benchmarks
Peer Average Claims18.0
Peer Average 30-Day Fills22.5
Peer Average Days Supply672
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 100.0% higher than the standard regional baseline profile for NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $16,426.91 across this reporting matrix range.

Provider Avg Cost Per Claim

$456.30

State Avg Cost Per Claim

$361.98

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pharmaceutical preparation of budesonide and formoterol fumarate that is used as an ANTI-ASTHMATIC AGENT and for the treatment of CHRONIC OBSTRUCTIVE PULMONARY DISEASE.

Therapeutic Applications

This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). It contains 2 medications: budesonide and formoterol. Budesonide belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Formoterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as formoterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. Before using this medication, it is important to learn how to use it properly. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed. See also How to Use section.

Cefuroxime

Generic Formulation: Cefuroxime AxetilSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 67
NY State Average Benchmarks
Peer Average Claims29.0
Peer Average 30-Day Fills30.2
Peer Average Days Supply255
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 62.1% less volume than the regional standard for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $113.34 across this reporting matrix range.

Provider Avg Cost Per Claim

$10.30

State Avg Cost Per Claim

$25.09

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A cephalosporin antibiotic.

Therapeutic Applications

Cefuroxime is used to treat a wide variety of bacterial infections. This medication is known as a cephalosporin antibiotic. It works by stopping the growth of bacteria. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Combivent Respimat

Generic Formulation: Ipratropium/Albuterol SulfateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 30
30-Day Fills 43.0
Days Supply 1,290
NY State Average Benchmarks
Peer Average Claims23.0
Peer Average 30-Day Fills28.3
Peer Average Days Supply835
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 30.4% more claims than the standard regional baseline profile for NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $22,294.11 across this reporting matrix range.

Provider Avg Cost Per Claim

$743.14

State Avg Cost Per Claim

$591.76

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to treat and prevent symptoms (wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes bronchitis and emphysema). This product contains 2 medications: ipratropium and albuterol (also known as salbutamol). Both drugs work by relaxing the muscles around the airways so that the airways open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school.

Daliresp

Generic Formulation: RoflumilastSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 49
30-Day Fills 49.0
Days Supply 343
NY State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills37.8
Peer Average Days Supply1,064
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 81.5% higher than the standard regional baseline profile for NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $5,310.62 across this reporting matrix range.

Provider Avg Cost Per Claim

$108.38

State Avg Cost Per Claim

$567.34

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Roflumilast is used to control and prevent symptoms (wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD which includes bronchitis). It should be used along with other medications (bronchodilators such as salmeterol, ipratropium) to treat COPD. It works by reducing the irritation and swelling of the airways. Controlling symptoms of breathing problems can decrease time lost from work or school. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath or wheezing. If sudden breathing problems occur, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Doxycycline Hyclate

Generic Formulation: Doxycycline HyclateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 24
30-Day Fills 24.0
Days Supply 156
NY State Average Benchmarks
Peer Average Claims28.0
Peer Average 30-Day Fills30.5
Peer Average Days Supply429
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $288.37 across this reporting matrix range.

Provider Avg Cost Per Claim

$12.02

State Avg Cost Per Claim

$23.85

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A synthetic tetracycline derivative with similar antimicrobial activity.

Therapeutic Applications

This medication is used to treat a wide variety of bacterial infections, including those that cause acne. This medication is also used to prevent malaria. This medication is known as a tetracycline antibiotic. It works by stopping the growth of bacteria. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Dupixent Syringe

Generic Formulation: DupilumabSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 14
30-Day Fills 14.0
Days Supply 392
NY State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills26.0
Peer Average Days Supply724
Conservative Utilization

This provider writes prescriptions for this formulation 41.7% less frequently than the standard regional baseline metric for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $54,069.90 across this reporting matrix range.

Provider Avg Cost Per Claim

$3,862.14

State Avg Cost Per Claim

$3,819.02

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain skin conditions (eczema, prurigo nodularis) and a certain esophagus problem (eosinophilic esophagitis). It is also used along with other medications to help control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma. In addition, dupilumab may be used to reduce symptoms caused by nasal polyps and the long-term swelling of the sinuses and nasal passage (chronic rhinosinusitis with nasal polyposis). Dupilumab belongs to a class of drugs known as monoclonal antibodies. It works by blocking certain natural proteins in your body (interleukin-4 and interleukin-13) that may cause inflammation and swelling. This medication should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Flovent Hfa

Generic Formulation: Fluticasone PropionateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 26
30-Day Fills 36.0
Days Supply 1,080
NY State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills34.1
Peer Average Days Supply1,020
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $10,578.64 across this reporting matrix range.

Provider Avg Cost Per Claim

$406.87

State Avg Cost Per Claim

$405.04

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A STEROID with GLUCOCORTICOID RECEPTOR activity that is used to manage the symptoms of ASTHMA; ALLERGIC RHINITIS, and ATOPIC DERMATITIS.

Therapeutic Applications

Fluticasone is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma. Controlling symptoms of asthma helps you maintain your normal activities and decreases time lost from work or school. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing swelling (inflammation) of the airways in the lungs to make breathing easier. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Fluticasone Propionate

Generic Formulation: Fluticasone PropionateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 47
30-Day Fills 84.0
Days Supply 2,520
NY State Average Benchmarks
Peer Average Claims57.0
Peer Average 30-Day Fills83.9
Peer Average Days Supply2,506
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $711.87 across this reporting matrix range.

Provider Avg Cost Per Claim

$15.15

State Avg Cost Per Claim

$15.88

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A STEROID with GLUCOCORTICOID RECEPTOR activity that is used to manage the symptoms of ASTHMA; ALLERGIC RHINITIS, and ATOPIC DERMATITIS.

Therapeutic Applications

Fluticasone is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma. Controlling symptoms of asthma helps you maintain your normal activities and decreases time lost from work or school. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing swelling (inflammation) of the airways in the lungs to make breathing easier. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Fluticasone-Salmeterol

Generic Formulation: Fluticasone Propion/SalmeterolSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 33
30-Day Fills 69.0
Days Supply 2,070
NY State Average Benchmarks
Peer Average Claims23.0
Peer Average 30-Day Fills31.5
Peer Average Days Supply944
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 43.5% more claims than the standard regional baseline profile for NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $10,261.88 across this reporting matrix range.

Provider Avg Cost Per Claim

$310.97

State Avg Cost Per Claim

$245.39

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). It contains 2 medications: fluticasone and salmeterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Salmeterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as salmeterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with one asthma-control medication (such as inhaled corticosteroid) or if your symptoms need combination treatment. Before using this medication, it is important to learn how to use it properly. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Incruse Ellipta

Generic Formulation: Umeclidinium BromideSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 67
30-Day Fills 104.0
Days Supply 3,120
NY State Average Benchmarks
Peer Average Claims31.0
Peer Average 30-Day Fills39.9
Peer Average Days Supply1,175
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 116.1% higher than the standard regional baseline profile for NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $39,243.39 across this reporting matrix range.

Provider Avg Cost Per Claim

$585.72

State Avg Cost Per Claim

$468.20

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Umeclidinium is used to control and prevent symptoms (such as wheezing, shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes bronchitis and emphysema). It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Umeclidinium belongs to a class of drugs known as anticholinergics. Controlling symptoms of breathing problems can decrease time lost from work or school. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If wheezing or sudden shortness of breath occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Levalbuterol Tartrate Hfa

Generic Formulation: Levalbuterol TartrateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 17
30-Day Fills 23.0
Days Supply 579
NY State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills25.5
Peer Average Days Supply675
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,151.99 across this reporting matrix range.

Provider Avg Cost Per Claim

$67.76

State Avg Cost Per Claim

$75.79

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Levalbuterol is used to prevent and treat wheezing and shortness of breath caused by breathing problems (such as asthma, chronic obstructive pulmonary disease). It is a quick-relief drug. Levalbuterol belongs to a class of drugs known as bronchodilators. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. This drug is not approved for use in children younger than 4 years due to increased risk of side effects (such as unusual fast breathing, worsening asthma). Ask your doctor or pharmacist for details.

Montelukast Sodium

Generic Formulation: Montelukast SodiumSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 192
30-Day Fills 340.0
Days Supply 9,116
NY State Average Benchmarks
Peer Average Claims55.0
Peer Average 30-Day Fills108.8
Peer Average Days Supply3,230
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 249.1% higher than the standard regional baseline profile for NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,936.79 across this reporting matrix range.

Provider Avg Cost Per Claim

$10.09

State Avg Cost Per Claim

$15.11

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Montelukast is used to control and prevent symptoms caused by asthma (such as wheezing and shortness of breath). It is also used before exercise to prevent breathing problems during exercise (bronchospasm). This medication can help decrease the number of times you need to use your quick relief inhaler. Montelukast is also used to relieve symptoms of hay fever and allergic rhinitis (such as sneezing, stuffy/runny/itchy nose). Since there are other allergy medications that may be safer (see also Warning section), this medication should be used for this condition only when you cannot take other allergy medications or they do not work well. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks or breathing problems. If an asthma attack or sudden shortness of breath occurs, use your quick-relief inhaler as prescribed. This drug works by blocking certain natural substances (leukotrienes) that may cause or worsen asthma and allergies. It helps make breathing easier by reducing swelling (inflammation) in the airways.

Nystatin

Generic Formulation: NystatinSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 155
NY State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills27.1
Peer Average Days Supply563
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 56.0% less volume than the regional standard for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $212.97 across this reporting matrix range.

Provider Avg Cost Per Claim

$19.36

State Avg Cost Per Claim

$25.86

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

Macrolide antifungal antibiotic complex produced by Streptomyces noursei, S. aureus, and other Streptomyces species. The biologically active components of the complex are nystatin A1, A2, and A3.

Therapeutic Applications

Nystatin is used to treat fungal skin infections. Nystatin is an antifungal that works by stopping the growth of fungus.

Prednisone

Generic Formulation: PrednisoneSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 275
30-Day Fills 336.0
Days Supply 6,794
NY State Average Benchmarks
Peer Average Claims44.0
Peer Average 30-Day Fills53.3
Peer Average Days Supply1,023
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 525.0% higher than the standard regional baseline profile for NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,314.35 across this reporting matrix range.

Provider Avg Cost Per Claim

$4.78

State Avg Cost Per Claim

$6.20

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.

Therapeutic Applications

Prednisone is used to treat conditions such as arthritis, blood disorders, breathing problems, severe allergies, skin diseases, cancer, eye problems, and immune system disorders. Prednisone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions.

Roflumilast

Generic Formulation: RoflumilastSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 38
30-Day Fills 59.0
Days Supply 1,766
NY State Average Benchmarks
Peer Average Claims17.0
Peer Average 30-Day Fills28.1
Peer Average Days Supply827
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 123.5% higher than the standard regional baseline profile for NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $11,797.07 across this reporting matrix range.

Provider Avg Cost Per Claim

$310.45

State Avg Cost Per Claim

$364.54

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Roflumilast is used to control and prevent symptoms (wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD which includes bronchitis). It should be used along with other medications (bronchodilators such as salmeterol, ipratropium) to treat COPD. It works by reducing the irritation and swelling of the airways. Controlling symptoms of breathing problems can decrease time lost from work or school. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath or wheezing. If sudden breathing problems occur, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Spiriva Handihaler

Generic Formulation: Tiotropium BromideSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 21
30-Day Fills 45.0
Days Supply 1,350
NY State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills33.4
Peer Average Days Supply989
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $23,354.76 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,112.13

State Avg Cost Per Claim

$759.00

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A scopolamine derivative and CHOLINERGIC ANTAGONIST that functions as a BRONCHODILATOR AGENT. It is used in the treatment of CHRONIC OBSTRUCTIVE PULMONARY DISEASE.

Therapeutic Applications

Tiotropium is used to control and prevent symptoms (such as wheezing, shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD which includes bronchitis and emphysema). It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Tiotropium belongs to a class of drugs known as anticholinergics. Controlling symptoms of breathing problems can decrease time lost from work or school. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden breathing problems. If wheezing or sudden shortness of breath occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Spiriva Respimat

Generic Formulation: Tiotropium BromideSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 85
30-Day Fills 127.0
Days Supply 3,810
NY State Average Benchmarks
Peer Average Claims31.0
Peer Average 30-Day Fills44.4
Peer Average Days Supply1,331
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 174.2% higher than the standard regional baseline profile for NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $67,801.91 across this reporting matrix range.

Provider Avg Cost Per Claim

$797.67

State Avg Cost Per Claim

$695.14

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A scopolamine derivative and CHOLINERGIC ANTAGONIST that functions as a BRONCHODILATOR AGENT. It is used in the treatment of CHRONIC OBSTRUCTIVE PULMONARY DISEASE.

Therapeutic Applications

Tiotropium is used to control and prevent symptoms (such as wheezing, shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD which includes bronchitis and emphysema). It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Tiotropium belongs to a class of drugs known as anticholinergics. Controlling symptoms of breathing problems can decrease time lost from work or school. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden breathing problems. If wheezing or sudden shortness of breath occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Stiolto Respimat

Generic Formulation: Tiotropium Br/Olodaterol HclSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 58
30-Day Fills 77.6
Days Supply 2,326
NY State Average Benchmarks
Peer Average Claims31.0
Peer Average 30-Day Fills42.9
Peer Average Days Supply1,286
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 87.1% higher than the standard regional baseline profile for NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $39,269.07 across this reporting matrix range.

Provider Avg Cost Per Claim

$677.05

State Avg Cost Per Claim

$633.88

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Controlling symptoms of breathing problems helps you stay active. This inhaler contains 2 medications: tiotropium and olodaterol. Both drugs work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Tiotropium belongs to a class of drugs known as anticholinergics. Olodaterol belongs to the class of drugs known as long-acting inhaled beta-agonists (LABAs). Both drugs are also known as bronchodilators. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If sudden breathing problems occur, use your quick-relief inhaler as prescribed. Tiotropium/olodaterol is not approved to treat asthma. People with asthma using long-acting inhaled beta agonists (such as olodaterol) without also using an inhaled corticosteroid may have an increased risk of serious (sometimes fatal) breathing problems.

Symbicort

Generic Formulation: Budesonide/Formoterol FumarateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 194
30-Day Fills 264.0
Days Supply 7,920
NY State Average Benchmarks
Peer Average Claims36.0
Peer Average 30-Day Fills49.7
Peer Average Days Supply1,490
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 438.9% higher than the standard regional baseline profile for NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $104,831.65 across this reporting matrix range.

Provider Avg Cost Per Claim

$540.37

State Avg Cost Per Claim

$516.71

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pharmaceutical preparation of budesonide and formoterol fumarate that is used as an ANTI-ASTHMATIC AGENT and for the treatment of CHRONIC OBSTRUCTIVE PULMONARY DISEASE.

Therapeutic Applications

This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). It contains 2 medications: budesonide and formoterol. Budesonide belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Formoterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as formoterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. Before using this medication, it is important to learn how to use it properly. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed. See also How to Use section.

Trelegy Ellipta

Generic Formulation: Fluticasone/Umeclidin/VilanterSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 234
30-Day Fills 364.0
Days Supply 10,920
NY State Average Benchmarks
Peer Average Claims55.0
Peer Average 30-Day Fills73.7
Peer Average Days Supply2,206
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 325.5% higher than the standard regional baseline profile for NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $240,890.71 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,029.45

State Avg Cost Per Claim

$849.96

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma and ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Controlling symptoms of breathing problems helps you stay active. This inhaler contains 3 medications: fluticasone, umeclidinium, and vilanterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing swelling of the airways in the lungs to make breathing easier. Umeclidinium belongs to a class of drugs known as anticholinergics and vilanterol is a LABA medication. Both drugs work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Both drugs are also known as bronchodilators. When used alone, long-acting beta agonists (such as vilanterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination products containing both an inhaled corticosteroid and long-acting beta agonist, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with two asthma-control medications (such as inhaled corticosteroid and long-acting beta agonist) or if your symptoms need combination treatment. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If sudden breathing problems occur, use your quick-relief inhaler as prescribed.

Ventolin Hfa

Generic Formulation: Albuterol SulfateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 50
30-Day Fills 75.9
Days Supply 2,019
NY State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills29.8
Peer Average Days Supply769
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 100.0% higher than the standard regional baseline profile for NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $5,628.65 across this reporting matrix range.

Provider Avg Cost Per Claim

$112.57

State Avg Cost Per Claim

$75.39

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.

Therapeutic Applications

Albuterol (also known as salbutamol) is used to treat wheezing and shortness of breath caused by breathing problems such as asthma. It is a quick-relief medication. Albuterol belongs to a class of drugs known as bronchodilators. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school.

Wixela Inhub

Generic Formulation: Fluticasone Propion/SalmeterolSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 14
30-Day Fills 20.0
Days Supply 600
NY State Average Benchmarks
Peer Average Claims21.0
Peer Average 30-Day Fills31.8
Peer Average Days Supply953
Conservative Utilization

This provider writes prescriptions for this formulation 33.3% less frequently than the standard regional baseline metric for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,778.76 across this reporting matrix range.

Provider Avg Cost Per Claim

$198.48

State Avg Cost Per Claim

$285.27

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). It contains 2 medications: fluticasone and salmeterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Salmeterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as salmeterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with one asthma-control medication (such as inhaled corticosteroid) or if your symptoms need combination treatment. Before using this medication, it is important to learn how to use it properly. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like MRS. LYMARIS GARCIA-MEDINA MD provides transparency into local medical care patterns within Hudson, NY.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Pulmonary Disease** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.